Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.77 |
| ▸ | MGLL | Q99685 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477493 | 1.00 | HSD11B1 (0.77) | HSD11B1MGLLRAB9AKMT2ALMNA | |
| SCHEMBL5476024 | 0.94 | HSD11B1 (0.87) | HSD11B1MGLLRAB9AKMT2ALMNA | |
| SCHEMBL5476018 | 0.94 | HSD11B1 (0.87) | HSD11B1MGLLRAB9AKMT2ALMNA | |
| SCHEMBL21926854 | 0.92 | HSD11B1 (0.64) | HSD11B1MGLLRAB9AKMT2ALMNA | |
| SCHEMBL5482366 | 0.90 | HSD11B1 (0.62) | HSD11B1MGLLRAB9AKMT2ALMNA | |
| SCHEMBL5482362 | 0.90 | HSD11B1 (0.62) | HSD11B1MGLLRAB9AKMT2ALMNA | |
| SCHEMBL5474375 | 0.90 | HSD11B1 (0.62) | HSD11B1MGLLRAB9AKMT2ALMNA | |
| SCHEMBL5474371 | 0.90 | HSD11B1 (0.62) | HSD11B1MGLLRAB9AKMT2ALMNA | |
| SCHEMBL21926546 | 0.84 | ALDH1A1 (0.55) | HSD11B1MGLLRAB9AKMT2AALDH1A1 | |
| SCHEMBL21926578 | 0.84 | ALDH1A1 (0.59) | HSD11B1KMT2AALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885MGLL 630/4885RAB9A 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.